Are Phage Lytic Proteins the Secret Weapon To Kill Staphylococcus aureus ?
Open Access
- 7 March 2018
- journal article
- review article
- Published by American Society for Microbiology in mBio
- Vol. 9 (1)
- https://doi.org/10.1128/mbio.01923-17
Abstract
Methicillin-resistant Staphylococcus aureus (MRSA) is one of the most threatening microorganisms for global human health. The current strategies to reduce the impact of S. aureus include a restrictive control of worldwide antibiotic use, prophylactic measures to hinder contamination, and the search for novel antimicrobials to treat human and animal infections caused by this bacterium. The last strategy is currently the focus of considerable research. In this regard, phage lytic proteins (endolysins and virion-associated peptidoglycan hydrolases [VAPGHs]) have been proposed as suitable candidates. Indeed, these proteins display narrow-spectrum antimicrobial activity and a virtual lack of bacterial-resistance development. Additionally, the therapeutic use of phage lytic proteins in S. aureus animal infection models is yielding promising results, showing good efficacy without apparent side effects. Nonetheless, human clinical trials are still in progress, and data are not available yet. This minireview also analyzes the main obstacles for introducing phage lytic proteins as human therapeutics against S. aureus infections. Besides the common technological problems derived from large-scale production of therapeutic proteins, a major setback is the lack of a proper legal framework regulating their use. In that sense, the relevant health authorities should urgently have a timely discussion about these new antimicrobials. On the other hand, the research community should provide data to dispel any doubts regarding their efficacy and safety. Overall, the appropriate scientific data and regulatory framework will encourage pharmaceutical companies to invest in these promising antimicrobials.Keywords
Funding Information
- Ministry of Science and Innovation Spain (AGL2015-65673-R)
- ERA-NET European Union (BLAAT ID: 67)
- Program of Science, Technology and Innovation Principado de Asturias (GRUPIN14-139)
- FEDER EU funds (GRUPIN14-139)
This publication has 79 references indexed in Scilit:
- The Phage Lytic Proteins from the Staphylococcus aureus Bacteriophage vB_SauS-phiIPLA88 Display Multiple Active Catalytic Domains and Do Not Trigger Staphylococcal ResistancePLOS ONE, 2013
- Enzyme-Based Listericidal NanocompositesScientific Reports, 2013
- In Vitro Activity against Staphylococcus aureus of a Novel Antimicrobial Agent, PRF-119, a Recombinant Chimeric Bacteriophage EndolysinAntimicrobial Agents and Chemotherapy, 2011
- A Novel Chimeric Lysin Shows Superiority to Mupirocin for Skin Decolonization of Methicillin-Resistant and -Sensitive Staphylococcus aureus StrainsAntimicrobial Agents and Chemotherapy, 2011
- Synergy between the phage endolysin LysH5 and nisin to kill Staphylococcus aureus in pasteurized milkInternational Journal of Food Microbiology, 2010
- Synergism between a Novel Chimeric Lysin and Oxacillin Protects against Infection by Methicillin-Resistant Staphylococcus aureusAntimicrobial Agents and Chemotherapy, 2010
- Nasal decolonization of Staphylococcus aureus with mupirocin: strengths, weaknesses and future prospectsJournal of Antimicrobial Chemotherapy, 2009
- Phage Lysin LysK Can Be Truncated to Its CHAP Domain and Retain Lytic Activity against Live Antibiotic-Resistant StaphylococciApplied and Environmental Microbiology, 2009
- Bacteriophage lysins as effective antibacterialsCurrent Opinion in Microbiology, 2008
- Lytic Activity of Recombinant Bacteriophage φ11 and φ12 Endolysins on Whole Cells and Biofilms of Staphylococcus aureusApplied and Environmental Microbiology, 2007